The Trade: Valeant’s Cost-Cutting Ethos May Yet Give Wall Street Indigestion

Valeant Pharmaceuticals’ lean business model risks harming its relationship with the Food and Drug Administration and hampering its competitiveness, Jesse Eisinger writes in The Trade.

via NYT > Business Day http://ift.tt/1ldELTV

via WordPress http://ift.tt/1AzfzRm